Sex differences in CSF biomarkers of Alzheimer’s disease

Michelle M. Mielke

Research output: Chapter in Book/Report/Conference proceedingChapter


The development of cerebrospinal fluid (CSF) biomarkers for Alzheimer’s disease (AD) and related disorders is rapidly progressing. Although the use of precision medicine methods has contributed to enhanced understanding of the AD pathophysiological changes and development of assays, one aspect not commonly considered is sex and gender differences. There are several ways in which sex can affect the measurement or interpretation of AD-related CSF biomarkers, including sex differences in biomarker concentrations and sex differences in the diagnosis or prognosis of the biomarker. This chapter highlights the impetus to consider sex differences in the development and interpretation of clinical assays for CSF biomarkers of AD.

Original languageEnglish (US)
Title of host publicationSex and Gender Differences in Alzheimer’s Disease
Number of pages17
ISBN (Electronic)9780128193440
StatePublished - Jan 1 2021


  • Alzheimer’s disease
  • Amyloid-beta
  • Cerebrospinal fluid
  • Dementia
  • Sex differences
  • Tau

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Sex differences in CSF biomarkers of Alzheimer’s disease'. Together they form a unique fingerprint.

Cite this